Caristo Diagnostics Presents AI Heart CT Data at ESC Congress 2026

Aug 31, 2026
Caristo Diagnostics presented new ESC Congress 2026 data showing that its FAI-Score biomarker can assess coronary inflammation from cardiac CT scans without contrast.

Caristo Diagnostics said in a press release that research led by University of Oxford presented at ESC Congress 2026 showed its FAI-Score biomarker can assess coronary inflammation using cardiac CT without contrast.

The company said the data showed the biomarker could identify higher risk in patients with a zero coronary calcium score. The findings use the same coronary inflammation biology and AI technology behind CaRi-Heart, Caristo's product for coronary inflammation assessment from routine coronary CT angiography.

Caristo also presented ORFAN-MAESTRIA research using its AI to predict stroke from routine cardiac CT. Other ESC Congress 2026 sessions covered the company's platform for cardiovascular risk assessment.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.